



Diabetes Industry Veteran Pawel Fludzinski, Ph.D. Named CEO of AmideBio

BOULDER, CO, May 16, 2018 – AmideBio LLC, a privately held biopharmaceutical company, announced today that Dr. Pawel Fludzinski has joined the Company as its new Chief Executive Officer. With his extensive background in the development of drugs targeting diabetes at Eli Lilly & Co, Dr. Fludzinski was selected as the ideal candidate to lead AmideBio’s development of its pipeline of drug candidates targeting metabolic diseases. Dr. Misha Plam, who has served as CEO since the Company’s inception, will continue as President and Chairman of the Board of Directors.

“I am honored and excited to assume the CEO role at AmideBio,” said Dr. Fludzinski. “AmideBio’s novel approach to developing glucose responsive insulins (GRI) promises to radically improve the treatment of diabetes. I look forward to leading the GRI effort as well as other growth opportunities.”

“AmideBio is very fortunate to have found someone so well suited to become our Chief Executive Officer,” commented Dr. Plam. “We are at a critical time as we develop a number of drug candidates and talk with potential collaborators and investors. Dr. Fludzinski has had a distinguished career at Lilly and fully appreciates the challenges and opportunities that the Company faces. I am absolutely delighted that he has agreed to join our effort.”

Previously, Dr. Fludzinski was Global Brand Development Leader within the Diabetes Business Unit at Lilly where he led a cross functional team through Phase 2, Phase 3 and global registration of TRULICITY®, Lilly’s once-a week agent for glycemic control in type 2 diabetes. He has held multiple executive leadership positions at Lilly in the United States, United Kingdom and Japan, encompassing roles in strategy, research, and drug development. In addition, he was one of the founding members of Lilly BioVentures. He holds a BS in chemistry from Rensselaer Polytechnic Institute, Troy NY, a Ph.D. in organic chemistry from the University of Rochester, Rochester NY, and was a National Institutes of Health Postdoctoral Fellow at Columbia University, New York City, NY.

About AmideBio:

AmideBio is a biotechnology company developing a pipeline of novel biotherapeutics by leveraging its knowhow to drive intelligent design of drug candidates targeting metabolic diseases. Its proprietary Cap-Clip™ production technology delivers high purity and difficult-to-manufacture BioPure™ peptides of any length with unprecedented purity for the pharmaceutical and biotech industry. AmideBio was founded in 2009 by Dr. Michael Stowell, Associate Professor of Molecular, Cellular and Developmental Biology at the University of Colorado, Boulder and Dr. Misha Plam, a serial entrepreneur.

For more information contact:

Dr. Misha Plam

President

T: (303) 641-3669

misha.plam@amidebio.com

www.amidebio.com

###